Artificial Liver Support System Improves One‐Year Prognosis of Patients With Hepatitis B Virus‐Associated Acute‐on‐Chronic Liver Failure
Journal of Gastroenterology and Hepatology · 2025
DOI: 10.1111/jgh.16883 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Xiaoqin Lan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Acute-On-Chronic Liver Failure, Liver, Artificial, Hepatitis B, Hepatitis B, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: National Science and Technology Major Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background & Aims Acute‐on‐chronic liver failure (ACLF) is a complex syndrome with limited treatment options. This study aims to investigate the impact of artificial liver support system (ALSS) on the one‐year prognosis of patients with Hepatitis B virus (HBV)‐associated ACLF.
Method
A retrospective study was conducted on 239 patients with HBV‐ACLF in Nanfang Hospital from January 2016 to June 2021. Patients were divided into the ALSS group ( n = 103) and the Standard Medical Therapy (SMT group, n = 136). Demographic, clinical, and laboratory data were collected before the first ALSS treatment for patients in ALSS group, while baseline data were collected in SMT group. According to receiving different ALSS modes, patients in ALSS group were divided into plasma exchange (PE) group and non‐PE group.
Result
The 12‐week and 1‐year liver transplant (LT) free survival rates in the ALSS group were significantly higher than that in the SMT group (65.05% vs 52.21%, p = 0.0011; 63.11% vs. 48.53%, p = 0.0006). ALSS therapy was the independent predictive factors associated with 12‐week and 1‐year mortality (hazard ratio, HR: 0.59, p = 0.04, and HR: 0.54, p = 0.01). Comparatively more ALSS‐related complications were observed in PE group. After Propensity Score Matching, the 12‐week and 1‐year LT‐free survival rates between PE and non‐PE group were similar (88% vs. 80%, p = 0.227, 88% vs. 80%, p = 0.227).
Conclusion
ALSS therapy is a safe and effective treatment for HBV‐ACLF. ALSS improves 1‐year prognosis of patients with HBV‐ACLF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Nanfang Hospital, Department of Hepatology, Zengcheng Branch, Southern Medical University, Guangzhou, China.
- State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangzhou, China.
ORCID-Profile: Changze Hong, Xiaofeng Zhang, Jinjun Chen
Förderung
- National Science and Technology Major Project
- National Natural Science Foundation of China
Zitieren
APA
Lan, X., Hong, C., Zhang, X., Zhou, L., Li, Y., Zhang, C., Mo, X., Zhou, J., Li, B., Qi, T., He, Q., Luo, W., Lai, Q., Ji, Y., Xu, Y., Liu, J., Zhou, F., & Chen, J. (2025). Artificial Liver Support System Improves One‐Year Prognosis of Patients With Hepatitis B Virus‐Associated Acute‐on‐Chronic Liver Failure. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16883
Vancouver
Lan X, Hong C, Zhang X, Zhou L, Li Y, Zhang C, et al. Artificial Liver Support System Improves One‐Year Prognosis of Patients With Hepatitis B Virus‐Associated Acute‐on‐Chronic Liver Failure. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.16883
BibTeX
@article{Lan2025,
author = {Lan, Xiaoqin and Hong, Changze and Zhang, Xiaofeng and Zhou, Ling and Li, Yuan and Zhang, Caili and Mo, Xingyan and Zhou, Jing and Li, Beiling and Qi, Tingting and He, Qinjun and Luo, Wenfan and Lai, Qintao and Ji, Yali and Xu, Ying and Liu, Junwei and Zhou, Fuyuan and Chen, Jinjun},
title = {Artificial Liver Support System Improves One‐Year Prognosis of Patients With Hepatitis B Virus‐Associated Acute‐on‐Chronic Liver Failure},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
doi = {10.1111/jgh.16883}
}
EUVIMED